Research To Practice | Oncology Videos

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49) PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24) Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44) Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38) NCPD information and select publications

Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics: Introduction (0:00) New Biology of Myelofibrosis (1:55) Novel Regulatory T-Cell Infusion Therapy (14:57) Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39) BET Inhibitors: Pelabresib (42:03) Navtemadlin (53:20) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 2: Novel Investigational Strategies — John Mascarenhas, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 1: Current Management of Myelofibrosis (MF) — Professor Claire Harrison CME information and select publications

Featuring perspectives from Dr Sunnie Kim, Ms Brooke Parker, Ms Michal Segal and Dr Manish Shah, including the following topics: Introduction: Clinical Presentation of Gastroesophageal Cancer (0:00) Management of Localized or Locally Advanced Gastroesophageal Cancers; Current and Future Role of Immune Checkpoint Inhibitors (21:44) Incorporation of Immunotherapeutic Strategies for HER2-Negative Metastatic Gastroesophageal Tumors (39:32) Role of Therapy Targeting CLDN18.2 in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (1:00:50) Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers (1:22:41) NCPD information and select publications

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics: Introduction: Actionable Genomic Alterations (0:00) ALK (9:49) ROS1 (22:22) HER2 (31:00) RET (38:52) NTRK (45:30) MET (46:31) Novel Targeted Strategies (49:09) BRAF (54:19) KRAS G12C (55:38) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting HER2, MET, BRAF and KRAS G12C — Joel W Neal, MD, PhD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1: Therapeutic Approaches Targeting ALK, ROS1, RET, TRK and NRG1 — Jessica J Lin, MD CME information and select publications

Featuring perspectives from Ms Kathryn M Lyle, Dr Ritu Salani, Ms Jaclyn Shaver and Dr Brian M Slomovitz, including the following topics: Introduction: Overview of Endometrial Cancer (0:00) First-Line Therapy for Advanced or Recurrent Endometrial Cancer (11:01) Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced Endometrial Cancer (39:09) Novel Investigational Strategies for Newly Diagnosed Advanced Endometrial Cancer (1:00:15) Incidence and Management of HER2-Positive Endometrial Cancer (1:17:52) NCPD information and select publications

Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 2: Other Available and Emerging Novel Therapies for NHL — Stephen M Ansell, MD, PhD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 1: Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies in Various Non-Hodgkin Lymphoma (NHL) Subtypes — Brian T Hill, MD, PhD CME information and select publications

Featuring perspectives from Dr Ian E Krop and Dr Sara M Tolaney, including the following topics: Introduction: Adjuvant CDK4/6 Inhibition (0:00) HER2-Positive Disease (11:13) PARP Inhibition (27:34) Antibody-Drug Conjugates (34:12) Up-Front Treatment of HR-Positive Metastatic Disease (46:28) CME information and select publications

Featuring perspectives from Dr Daniel George, Dr Leonard G Gomella and Dr Evan Y Yu, moderated by Dr George, including the following topics: Introduction (0:00) Current Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Gomella (3:42) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr Yu (35:37) Emerging Role of AKT Inhibition for mHSPC — Dr George (1:06:18) CME information and select publications

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, including the following topics: Systemic Mastocytosis — Dr Bose (0:00) Myelofibrosis — Dr Kuykendall (24:46) CME information and select publications

Featuring perspectives from Dr Thomas A Abrams and Dr Ahmed Omar Kaseb, including the following topics: Current Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Abrams (0:00) Promising Novel Approaches to HCC Management — Dr Kaseb (33:46) CME information and select publications

Featuring perspectives from Dr Natalie S Callander and Dr Thomas Martin, including the following topics: Introduction (0:00) Current and Emerging Therapeutic Approaches for Multiple Myeloma — Dr Callander (4:42) CAR T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Martin (31:16) CME information and select publications

Featuring perspectives from Dr Farshid Dayyani, Ms Caroline Kuhlman, Dr Philip A Philip and Ms Amanda K Wagner, including the following topics: Introduction: Initial Management of Pancreatic Adenocarcinoma (PAD) (0:00) Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD (19:01) Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (54:38) Importance of Palliative Care for Advanced PAD (1:06:09) Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD (1:14:59) Promising Investigational Strategies for PAD (1:26:56) NCPD information and select publications

Featuring an interview with Dr Rafael Fonseca, including the following topics: Safe management of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma (MM) (0:00) Sequencing bispecific antibodies and CAR T-cell therapy (10:40) Available data with and potential future clinical integration of belantamab mafodotin in the management of MM (16:03) Optimizing maintenance therapy for patients with MM (31:11) Novel management strategies for smoldering myeloma (36:29) Role of anti-CD38 antibodies in the up-front management of MM (41:41) Available data with cereblon E3 ligase modulatory drugs for MM (47:45) CME information and select publications

Featuring a slide presentation and related discussion from Dr Rafael Fonseca, including the following topics: Recent updates from ASH 2024 on the up-front use of anti-CD38 monoclonal antibodies for multiple myeloma (MM) (0:00) Updated data with belantamab mafodotin for the management of MM (12:39) Updated findings with chimeric antigen receptor T cell therapy for the management of MM (17:52) ASH 2024 updates with other novel agents and strategies for the management of MM (21:32) CME information and select publications

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00) Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13) Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05. Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06) VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P. Selective review of trials of oral SERDs in the adjuvant setting (11:27) A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054 CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, MD, including the following topics: Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Janjigian (0:00) Available and Emerging Targeted Therapeutic Approaches for Gastroesophageal Cancers — Dr Klempner(28:38) CME information and select publications

Featuring an interview with Dr Lindsey Roeker, including the following topics: Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00) Safety of BTK inhibitors in older and frail patients with CLL (3:41) Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20) Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32) Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31) Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16) Sequencing, tolerability and future development involving pirtobrutinib (25:57) Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28) Clinical considerations in the management of Richter's transformation (38:14) Survival outcomes and quality of life for patients with CLL (41:02) Ongoing and future efforts to improve CLL treatment outcomes (45:01) CME information and select publications

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics: Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00) Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax (7:03) Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35) Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28) Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease (15:52) Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12) Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor (19:38) Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment (22:15) Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13) Available data with epcoritamab monotherapy for R/R CLL (26:58) The emerging pharmacologic class of BTK degraders (29:04) CME information and select publications

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: EZH2 Inhibitors for Follicular Lymphoma (FL) (0:00) Bruton Tyrosine Kinase Inhibitors for FL (5:43) Anti-CD19 Antibodies for FL (9:40) Other Novel Agents Under Clinical Development for FL (18:50) Case: A woman in her early 80s with multiple comorbidities and relapsed FL (23:06) Case: A man in his early 40s with high-risk progressive FL that did not achieve deep remission with prior therapy (27:07) Case: A woman in her early 70s with rheumatoid arthritis and relapsed FL (33:46) CME information and select publications

Featuring perspectives from Dr Shilpa Gupta and Dr Jonathan E Rosenberg, including the following topics: Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Gupta (0:00) Optimizing the Treatment of Metastatic UBC — Dr Rosenberg (21:52) CME information and select publications

Featuring perspectives from Dr Paul E Oberstein and Dr Philip A Philip, including the following topics: Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Oberstein (0:00) Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr Philip(30:57) CME information and select publications

Featuring an interview with Dr Jennifer Crombie, including the following topics: Overview of similarities and differences among CD20 x CD3 targeted bispecific antibodies for the treatment of lymphomas (0:00) Optimal integration of CD20 x CD3 bispecific antibodies into treatment algorithms for lymphomas (9:40) Case: A man in his late 60s with relapsed follicular lymphoma (FL) who received mosunetuzumab (23:52) Case: A man in his late 80s with transformed, double-hit diffuse large B-cell lymphoma (DLBCL) who received epcoritamab (28:46) Case: A woman in her early 70s with recurrent FL who received odronextamab on the ELM-1 trial (34:06) Case: A man in his early 80s with multiregimen-relapsed DLBCL who receives glofitamab (43:19) CME information and select publications

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications

Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics: Introduction (0:00) Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04) First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation — Dr Liu (26:59) CME information and select publications

Featuring perspectives from Dr Christopher Lieu and Dr Kanwal Raghav, including the following topics: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu (0:00) Recent Advances in the Management of Metastatic CRC — Dr Raghav (32:58) CME information and select publications

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00) Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50) Published Clinical Data Involving Axi-cel (10:24) Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34) Published Clinical Data Involving Tis-cel (19:47) Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43) Published Clinical Data Involving Liso-cel (26:05) Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48) Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35) Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59) CME information and select publications

Featuring perspectives from Dr Emmanuel S Antonarakis and Prof Karim Fizazi, including the following topics: Introduction: Quality of Life (0:00) PARP Inhibition (PARPi) (7:15) M0 Disease (23:18) Metastatic Hormone-Sensitive Prostate Cancer (34:33) Radiopharmaceuticals (46:16) Other Novel Investigational Approaches for Metastatic Castration-Resistant Prostate Cancer (54:53) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Emmanuel S Antonarakis, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer (PC) — Professor Karim Fizazi, MD, PhD CME information and select publications

Featuring perspectives from Dr Christopher Flower and Dr Krish Patel, including the following topics: Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Non-Hodgkin Lymphoma (NHL) — Dr Patel (0:00) Other Available and Emerging Novel Therapies for NHL — Dr Flowers (22:07) CME information and select publications

Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics: Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00) Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38) CME information and select publications

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Ms Monica Averia, Ms Kathleen D Burns and Dr William K Oh, including the following topics: Introduction: Overview of Prostate Cancer (0:00) Recent Advances in the Treatment of Nonmetastatic Prostate Cancer (8:36) Treatment Approaches for Metastatic Hormone-Sensitive Prostate Cancer (30:01) Current Role of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (47:41) Current and Future Role of Radiopharmaceuticals in mCRPC (1:09:57) NCPD information and select publications

Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics: Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00) CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06) Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17) Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34) Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41) ADCs for HER2-Positive Breast Cancer (46:30) HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26) ADCs for Advanced Triple-Negative Breast Cancer (58:29) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer | Faculty Presentation 2: HER2-Positive Breast Cancer and Triple-Negative Breast Cancer (TNBC) — Nancy U Lin, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer | Faculty Presentation 1: HR-Positive Breast Cancer — Rebecca A Dent, MD, MSc CME information and select publications

Featuring perspectives from Dr Jennifer R Brown and Prof Paolo Ghia, including the following topics: Introduction: The Chronic Lymphocytic Leukemia (CLL) Experience — 2000 to 2025 (0:00) Current Therapy Options with Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (9:42) Role of Venetoclax in the Treatment of CLL (26:52) AMPLIFY Trial and Other Novel BTK Inhibitor and Bcl-2 Inhibitor Combination Strategies (32:29) Noncovalent BTK Inhibitor Pirtobrutinib (46:47) CAR T-Cell Therapy; Novel Agents (56:12) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 2: Novel Agents and Combination Strategies — Jennifer R Brown, MD, PhD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Role of Covalent Bruton Tyrosine Kinase Inhibitors and Bcl-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia, MD, PhD CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jennifer Filipi, Dr David M O'Malley and Dr Shannon N Westin, including the following topics: Introduction: Overview of Ovarian Cancer (OC) Management (0:00) Genetic Testing for Newly Diagnosed Advanced OC (14:31) Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC (22:46) Other Available and Investigational Novel Strategies for OC (43:56) Current and Future Role of Mirvetuximab Soravtansine in OC Treatment (1:19:24) NCPD information and select publications

Featuring perspectives from Dr Rahul Aggarwal and Dr William K Oh, including the following topics: Hormonal Therapy for Patients with Prostate Cancer — Dr Oh (0:00) Other Available and Emerging Therapeutic Approaches — Dr Aggarwal (27:14) CME information and select publications

Featuring slide presentations and related discussion from Dr Hanny Al-Samkari, Dr James B Bussel and Prof Nichola Cooper, including the following topics: Introduction (0:00) Clinical Manifestations and Initial Management of Immune Thrombocytopenia (ITP) — Dr Al-Samkari (10:24) Second- and Later-Line Therapies for ITP — Dr Bussel (1:00:51) Tolerability and Other Practical Considerations with Available Treatment Strategies for Persistent/Chronic ITP — Prof Cooper (1:28:08) CME information and select publications

Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics: Introduction (0:00) Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59) Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16) CME information and select publications